rs118161496
Variant names:
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BS1_SupportingBS2
The NM_025152.3(NUBPL):c.815-27T>C variant causes a intron change. The variant allele was found at a frequency of 0.00373 in 1,571,878 control chromosomes in the GnomAD database, including 22 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). There are indicators that this mutation may affect the branch point..
Frequency
Genomes: 𝑓 0.0034 ( 3 hom., cov: 32)
Exomes 𝑓: 0.0038 ( 19 hom. )
Consequence
NUBPL
NM_025152.3 intron
NM_025152.3 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 3.77
Genes affected
NUBPL (HGNC:20278): (NUBP iron-sulfur cluster assembly factor, mitochondrial) This gene encodes a member of the Mrp/NBP35 ATP-binding proteins family. The encoded protein is required for the assembly of the respiratory chain NADH dehydrogenase (complex I), an oligomeric enzymatic complex located in the inner mitochondrial membrane. Mutations in this gene cause mitochondrial complex I deficiency. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -5 ACMG points.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.00339 (516/152374) while in subpopulation NFE AF= 0.00442 (301/68042). AF 95% confidence interval is 0.00401. There are 3 homozygotes in gnomad4. There are 271 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAd4 at 3 AR gene
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes 0.00340 AC: 517AN: 152256Hom.: 3 Cov.: 32
GnomAD3 genomes
AF:
AC:
517
AN:
152256
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00345 AC: 857AN: 248676Hom.: 10 AF XY: 0.00349 AC XY: 471AN XY: 134910
GnomAD3 exomes
AF:
AC:
857
AN:
248676
Hom.:
AF XY:
AC XY:
471
AN XY:
134910
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00377 AC: 5351AN: 1419504Hom.: 19 Cov.: 25 AF XY: 0.00373 AC XY: 2645AN XY: 709074
GnomAD4 exome
AF:
AC:
5351
AN:
1419504
Hom.:
Cov.:
25
AF XY:
AC XY:
2645
AN XY:
709074
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome 0.00339 AC: 516AN: 152374Hom.: 3 Cov.: 32 AF XY: 0.00364 AC XY: 271AN XY: 74508
GnomAD4 genome
AF:
AC:
516
AN:
152374
Hom.:
Cov.:
32
AF XY:
AC XY:
271
AN XY:
74508
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1
AN:
3476
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:7Uncertain:6
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Mitochondrial complex 1 deficiency, nuclear type 21 Pathogenic:4Uncertain:2
| Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
| Uncertain significance, criteria provided, single submitter | clinical testing | Undiagnosed Diseases Network, NIH | Aug 24, 2020 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 08, 2024 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Institute for Genomic Medicine (IGM) Clinical Laboratory, Nationwide Children's Hospital | Jun 15, 2018 | [ACMG/AMP: PS3, PP3, PP5, BS1] This alteration is supported by well-established in vitro or in vivo functional studies to have a damaging effect on protein function or splicing [PS3], is predicted to be damaging by multiple functional prediction tools [PP3], was reported as a pathogenic/likely pathogenic alteration by a reputable source (ClinVar or other correspondence from a clinical testing laboratory) [PP5], has an allele frequency that is greater than expected for the associated disease [BS1]. - |
| Uncertain significance, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Oct 19, 2020 | Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as 3B-VUS. Following criteria are met: 0102 - Loss-of-function is a known mechanism of disease for this gene. (N) 0106 - This gene is known to be associated with autosomal recessive disease. (N) 0210 - Splice site variant (canonical or non-canonical) proven to affect splicing/expression of the transcript with a known effect on protein structure. Functional studies showed three alternate transcripts were generated as a result of aberrant splicing from the allele with this variant: one transcript with normal splicing, one with exon 10 skipped resulting in a frameshift but no nonsense-mediated decay (NMD), and a third transcript that utilised a cryptic splice site resulting in a frameshift and NMD (PMIDs: 22072591, 32518176). (P) 0251 - Variant is heterozygous. (N) 0305 - Variant is present in gnomAD >=0.01 and <0.03 for a recessive condition (972 heterozygotes, 10 homozygotes). (N) 0705 - No comparable variants have previous evidence for pathogenicity. (N) 0803 - Low previous evidence of pathogenicity in unrelated individuals. An allele harbouring this variant in cis with a second variant (p.(Gly56Arg)) has been reported as pathogenic in many patients, majority of whom were in compound heterozygous state with a pathogenic allele (PMIDs: 22072591, 25245479, 23553477). However, an allele harbouring this variant without the p.(Gly56Arg) variant has been associated with disease in one family (PMID: 32518176). (P) 1001 - Strong functional evidence supporting abnormal protein function. Functional studies showed levels of NUBPL mRNA and protein were decreased in the fibroblast cells heterozygous for this variant alone (PMID: 22072591). (P) 1205 - Variant is maternally inherited. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 20, 2021 | - - |
not provided Pathogenic:2Uncertain:2
| Uncertain significance, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Jan 09, 2017 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jul 09, 2024 | PP1, PP3, PM3, PS3 - |
| Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2023 | NUBPL: PM3:Strong, PS3:Moderate, PM2:Supporting, PP3, BS2 - |
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 14, 2017 | Expression studies of the c.815-27 T>C sequence change found that this variant impairs mRNA splicing resulting in a 80% decrease in complex I assembly and function (Tucker et al., 2012; Wydro et al., 2013). Therefore, based on the currently available information, the c.815-27 T>C variant is a strong candidate for a pathogenic variant; however, the possibility that it is a benign variant cannot be excluded. - |
Inborn genetic diseases Pathogenic:1
| Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 13, 2021 | The c.815-27T>C intronic alteration consists of a T to C substitution 27 nucleotides before coding exon 10 in the NUBPL gene and is predicted to affect the native branch site. Based on data from the Genome Aggregation Database (gnomAD) database, the NUBPL c.815-27T>C alteration was observed in 0.35% (992/280082) of total alleles studied (including 10 homozygotes), with a frequency of 1.24% (310/24978) in the European (Finnish) subpopulation. The [c.166G>A (p.G56R); c.815-27T>C] complex allele has been reported in the homozygous state, compound heterozygous state, and confirmed in trans with a second pathogenic allele in multiple unrelated patients with mitochondrial encephalomyopathy (Calvo, 2010; Kevelam, 2013). Emerging evidence is suggestive that the NUBPL [c.166G>A (p.G56R); c.815-27T>C] complex allele is likely pathogenic when these alterations are in cis; however, the clinical significance of these alterations in isolation remains uncertain. The c.815-27T nucleotide is highly conserved in available vertebrate species. Functional analysis of cultured fibroblasts from a patient bearing the [c.166G>A (p.G56R); c.815-27T>C] complex allele in trans with a complex rearrangement, as well as a control patient who was heterozygous for only the c.815-27T>C alteration, demonstrated an aberrant RT-PCR pattern with three distinct transcripts: wild-type, a lengthened transcript resulting from a cryptic splice site which introduces an additional 72 bp and results in a frameshift (p.G272Vfs*11), as well as a truncated transcript generated due to exon 10 skipping resulting in a frameshift (p.D273Qfs*31) (Tucker, 2012). Analysis by qRT-PCR and Western blot showed that the heterozygous control with only the c.815-27T>C alteration had reduced mRNA expression (74%) and protein expression (59%) compared to wild type controls, and the patient with the [c.166G>A (p.G56R); c.815-27T>C] complex allele and complex rearrangement on the other allele had more significant reduction in mRNA expression (15%) and undetectable protein expression (Tucker, 2012). No defective function was identified when the protein with the G56R missense change was over-expressed (Tucker, 2012). The p.D273Qfs*31 transcript is completely non-functional in yeast assays (Wydro, 2013; Maclean, 2018). In silico splice site analysis predicts that the c.815-27T>C alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. Based on the available evidence, this alteration is classified as likely pathogenic. - |
not specified Uncertain:1
| Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 12, 2024 | Variant summary: NUBPL c.815-27T>C is located at a position not widely known to affect splicing. Consensus agreement among computation tools predict no significant impact on normal splicing. At least one publication reports experimental evidence that this variant affects mRNA splicing (Tucker_2012, Kimonis_2021, Calvo_2010). The variant allele was found at a frequency of 0.0037 in 1571878 control chromosomes in the gnomAD database (v4), including 22 homozygotes. The observed variant frequency exceeds the estimated maximal expected allele frequency for a pathogenic variant in NUBPL causing Mitochondrial Complex 1 Deficiency, Nuclear Type 21 phenotype. c.815-27T>C has been reported in the literature in multiple individuals affected with Mitochondrial Complex 1 Deficiency, Nuclear Type 21 (Calvo_2010, Kevelam_2013, Haskell_2018, Maclean_2018, Kimonis_2021), however it is usually observed in cis with the c.166G>A (p.G56R) variant. These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein expression, finding that a heterozygous control with the variant exhibited far lower expression of NUBPL protein (Tucker_2012). The following publications have been ascertained in the context of this evaluation (PMID: 20818383, 23553477, 22072591, 32518176, 29982452, 29417091). ClinVar contains an entry for this variant (Variation ID: 50317). There is not enough evidence at this time to determine if this variant is associated with disease in isolation. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. - |
Mitochondrial complex I deficiency Uncertain:1
| Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 16, 2024 | The c.815-27T>C variant in NUBPL is typically observed as a compound allele (in cis) with the c.166G>A [p.G56R] variant in individuals with mitochondrial complex I deficiency. By itself, it has been reported in at least one individual with mitochondrial complex I deficiency and an another variant in trans, and segregated with disease in at least 1 sibling (Kimonis 2021 PMID: 32518176; Maclean 2018 PMID:29982452). This variant has also been identified in 1.28% (819/63974) of European (Finnish) chromosomes, including 22 homozygotes, by gnomAD (http://gnomad.broadinstitute.org, v4.0.0) and reported in ClinVar (Variation ID 50317). This variant is located in the splice branch site, and computational prediction tools suggest an impact on splicing. An RT-PCR study demonstrated that this variant results in three transcripts: wild-type, the use of a cryptic acceptor site (p.G272VfsX11), or skipping of exon 10 (p.D273QfsX31). In addition, in vitro functional studies demonstrated that patient cells express reduced levels of the wild-type transcript, possibly as a result of degradation of a variant transcript by NMD (Tucker 2012 PMID: 22072591). Overall, it is unclear if this variant in isolation causes disease or whether it acts in synergy with the p.G56R variant. Therefore, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM3, PP1, PP3, PS3_Supporting, BS1_Supporting. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
BranchPoint Hunter
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: -45
DS_AL_spliceai
Position offset: 27
Find out detailed SpliceAI scores and Pangolin per-transcript scores at